193 related articles for article (PubMed ID: 32320041)
1. Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa.
Piccerillo A; El Hachem M; De Vito R; De Luca EV; Peris K
JAMA Dermatol; 2020 Jun; 156(6):708-710. PubMed ID: 32320041
[No Abstract] [Full Text] [Related]
2. Combined anti-inflammatory and low-dose antiproliferative therapy for squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.
Reimer A; Lu S; He Y; Bruckner-Tuderman L; Technau-Hafsi K; Meiss F; Has C; von Bubnoff D
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):e1-e3. PubMed ID: 31374134
[No Abstract] [Full Text] [Related]
3. Targeting the Jak/Signal Transducer and Activator of Transcription 3 Pathway with Ruxolitinib in a Mouse Model of Recessive Dystrophic Epidermolysis Bullosa-Squamous Cell Carcinoma.
Jacków J; Rami A; Hayashi R; Hansen C; Guo Z; DeLorenzo D; Pappalardo A; Alvarez Cespedes D; Kim AL; Perez-Lorenzo R; Owens DM; Christiano AM
J Invest Dermatol; 2021 Apr; 141(4):942-946. PubMed ID: 33069729
[No Abstract] [Full Text] [Related]
4. Cemiplimab treatment of squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa.
Vasilev P; Kalev D; Karamanliev M; Dimitrov D; Troyanova P; Yordanova I
J Dtsch Dermatol Ges; 2023 Mar; 21(3):295-297. PubMed ID: 36855845
[No Abstract] [Full Text] [Related]
5. Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma.
Kim M; Li M; Intong LR; Tran K; Melbourne W; Marucci D; Bucci J; de Souza P; Mallesara G; Murrell DF
Br J Dermatol; 2013 Jul; 169(1):208-10. PubMed ID: 23398414
[No Abstract] [Full Text] [Related]
6. Good clinical response to cemiplimab in a young patient with locally advanced cutaneous squamous cell carcinoma on preexisting recessive dystrophic epidermolysis bullosa.
Ciurescu D; Condruz S; Irimie M
Acta Dermatovenerol Alp Pannonica Adriat; 2024 May; 33(3):actaapa.2024.14. PubMed ID: 38808531
[TBL] [Abstract][Full Text] [Related]
7. Understanding the pathogenesis of recessive dystrophic epidermolysis bullosa squamous cell carcinoma.
South AP; O'Toole EA
Dermatol Clin; 2010 Jan; 28(1):171-8. PubMed ID: 19945632
[TBL] [Abstract][Full Text] [Related]
8. A recurrent nonsense mutation occurring as a de novo event in a patient with recessive dystrophic epidermolysis bullosa.
Cuadrado-Corrales N; Sánchez-Jimeno C; García M; Ayuso C; De Lucas R; Vicario JL; Conti CJ; Zambruno G; Escamez MJ; Del Rio M
Dermatology; 2011; 223(3):219-21. PubMed ID: 21849769
[No Abstract] [Full Text] [Related]
9. Canakinumab in recessive dystrophic epidermolysis bullosa: a novel unexpected weapon for non-healing wounds?
Annicchiarico G; Lopalco G; Morgese MG; Cantarini L; Iannone F
Clin Exp Rheumatol; 2016; 34(5):961-962. PubMed ID: 26885873
[No Abstract] [Full Text] [Related]
10. De novo anti-type VII collagen antibodies in patients with recessive dystrophic epidermolysis bullosa.
Woodley DT; Cogan J; Wang X; Hou Y; Haghighian C; Kudo G; Keene DR; Chen M
J Invest Dermatol; 2014 Apr; 134(4):1138-1140. PubMed ID: 24213372
[No Abstract] [Full Text] [Related]
11. Epidermolysis Bullosa (EB) Acquisita in an Adult Patient with Previously Unrecognized Mild Dystrophic EB and Biallelic COL7A1 Mutations.
Guerra L; Condorelli AG; Fortugno P; Calabresi V; Pedicelli C; Di Zenzo G; Castiglia D
Acta Derm Venereol; 2018 Apr; 98(4):411-415. PubMed ID: 29182795
[TBL] [Abstract][Full Text] [Related]
12. Dominant Dystrophic Epidermolysis Bullosa Pruriginosa Responding to Naltrexone Treatment.
Pallesen KAU; Lindahl KH; Bygum A
Acta Derm Venereol; 2019 Nov; 99(12):1195-1196. PubMed ID: 31453628
[No Abstract] [Full Text] [Related]
13. Recessive dystrophic epidermolysis bullosa-associated squamous-cell carcinoma: an enigmatic entity with complex pathogenesis.
Rodeck U; Uitto J
J Invest Dermatol; 2007 Oct; 127(10):2295-6. PubMed ID: 17853916
[TBL] [Abstract][Full Text] [Related]
14. Update on the pathogenesis of squamous cell carcinoma development in recessive dystrophic epidermolysis bullosa.
Kim M; Murrell DF
Eur J Dermatol; 2015 Apr; 25 Suppl 1():30-2. PubMed ID: 26083672
[TBL] [Abstract][Full Text] [Related]
15. Genetic Profiles of Squamous Cell Carcinomas Associated with Recessive Dystrophic Epidermolysis Bullosa Unveil NOTCH and TP53 Mutations and an Increased MYC Expression.
Sans-DeSanNicolas L; Caratú G; Vidal-Cortés O; Sanchez-Redondo S; Ferrer B; Mancuso F; González-Sanchez E; Pérez-Alea M; McGrail K; Hernandez-Losa J; Bodet D; Vivancos A; Garcia-Patos V; Recio JA
J Invest Dermatol; 2018 Jun; 138(6):1423-1427. PubMed ID: 29291383
[No Abstract] [Full Text] [Related]
16. [Squamous cell cancers in Hallopeau-Siemens recessive dystrophic epidermolysis bullosa].
Otte HG; Stieler W; Anton-Lamprecht I
Hautarzt; 1990 Sep; 41(9):494-8. PubMed ID: 2249946
[TBL] [Abstract][Full Text] [Related]
17. Characterization of patients with dystrophic epidermolysis bullosa for collagen VII therapy.
Gorell ES; Nguyen N; Siprashvili Z; Marinkovich MP; Lane AT
Br J Dermatol; 2015 Sep; 173(3):821-3. PubMed ID: 25703736
[No Abstract] [Full Text] [Related]
18. Squamous cell carcinoma secondary to recessive dystrophic epidermolysis bullosa. A report of 4 patients with 17 primary cutaneous malignancies.
Newman C; Wagner RF; Tyring SK; Spigel GT
J Dermatol Surg Oncol; 1992 Apr; 18(4):301-5. PubMed ID: 1560154
[TBL] [Abstract][Full Text] [Related]
19. Wound healing deficits in severe generalized recessive dystrophic epidermolysis bullosa along anticancer treatment with cetuximab.
Medek K; Koelblinger P; Koller J; Diem A; Ude-Schoder K; Bauer JW; Laimer M
J Dtsch Dermatol Ges; 2019 Apr; 17(4):448-450. PubMed ID: 30821421
[No Abstract] [Full Text] [Related]
20. Revertant mosaicism in recessive dystrophic epidermolysis bullosa.
Almaani N; Nagy N; Liu L; Dopping-Hepenstal PJ; Lai-Cheong JE; Clements SE; Techanukul T; Tanaka A; Mellerio JE; McGrath JA
J Invest Dermatol; 2010 Jul; 130(7):1937-40. PubMed ID: 20357813
[No Abstract] [Full Text] [Related]
[Next] [New Search]
